Someone at Novartis (NVS) screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia
Novartis may have received the letter from the FDA,which triggered an internal communication. Formal announcement and posting likely this coming week.